Quote | Lyra Therapeutics Inc. (NASDAQ:LYRA)
Last: | $0.272 |
---|---|
Change Percent: | 0.0% |
Open: | $0.28 |
Close: | $0.272 |
High: | $0.2851 |
Low: | $0.2664 |
Volume: | 822,177 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Lyra Therapeutics Inc. (NASDAQ:LYRA)
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
2023-04-25 08:55:36 ET Lyra Therapeutics ( NASDAQ: LYRA ) said it had resumed screening and enrollment for its second Phase 3 clinical trial of LYR-210 to treat chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant and acts as an alternative to sinus surgery...
Message Board Posts | Lyra Therapeutics Inc. (NASDAQ:LYRA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: LYRA 22% v5,2M c5.28 f13M H6.10 ML3.81 | znewcar1 | investorshangout | 04/09/2022 2:01:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...